Rhumbline Advisers Purchases 25,056 Shares of Sana Biotechnology, Inc. (NASDAQ:SANA)

Rhumbline Advisers lifted its position in Sana Biotechnology, Inc. (NASDAQ:SANA) by 16.0% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 181,903 shares of the company’s stock after acquiring an additional 25,056 shares during the period. Rhumbline Advisers owned 0.08% of Sana Biotechnology worth $993,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Sana Biotechnology by 20.6% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,858 shares of the company’s stock worth $163,000 after purchasing an additional 5,090 shares during the period. Bank of New York Mellon Corp grew its stake in shares of Sana Biotechnology by 26.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 431,744 shares of the company’s stock worth $2,357,000 after buying an additional 90,423 shares during the last quarter. Clarius Group LLC increased its position in Sana Biotechnology by 34.9% during the 2nd quarter. Clarius Group LLC now owns 63,184 shares of the company’s stock valued at $345,000 after buying an additional 16,359 shares in the last quarter. Zimmer Partners LP purchased a new position in Sana Biotechnology during the first quarter valued at $2,025,000. Finally, Baker BROS. Advisors LP boosted its holdings in Sana Biotechnology by 19.0% in the first quarter. Baker BROS. Advisors LP now owns 2,380,949 shares of the company’s stock worth $23,809,000 after acquiring an additional 380,949 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Trading Down 8.0 %

Shares of SANA opened at $4.25 on Monday. The firm has a market cap of $941.39 million, a PE ratio of -2.78 and a beta of 1.45. Sana Biotechnology, Inc. has a 1-year low of $2.74 and a 1-year high of $12.00. The firm has a fifty day simple moving average of $5.39 and a two-hundred day simple moving average of $7.04.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Thursday, August 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.04). As a group, research analysts forecast that Sana Biotechnology, Inc. will post -1.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on SANA. HC Wainwright lowered their price target on Sana Biotechnology from $12.00 to $11.00 and set a “buy” rating for the company in a research report on Friday, August 9th. Citigroup upped their target price on shares of Sana Biotechnology from $8.00 to $15.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Rodman & Renshaw started coverage on shares of Sana Biotechnology in a report on Wednesday, June 26th. They set a “buy” rating and a $16.00 price target on the stock.

Sana Biotechnology Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.